Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai is set to market Finland-based Orion's breast cancer drug Fareston (toremifene citrate) and Parkinson’s disease treatment Eldepryl (selegiline hydrochloride).
Subscribe to our email newsletter
As per the terms of the deal, Orion will license the Chinese marketing rights of these two drugs to Eisai.
Eisai will distribute the drugs through its Chinese subsidiary, Eisai China.
Fareston, which contains the active substance toremifene, is used to treat hormone-dependent metastatic breast cancer in women who have been through the menopause.
Eldepryl is used in conjunction with levodopa-containing agents for the treatment of Parkinson’s disease in patients who have previously had an inadequate response when treated with levodopa therapies alone.